The medtech startup founded by physician and Farapulse inventor Steven Mickelsen is preparing to begin a pivotal study of ...

Field Medical Inc. continues to reap funding from investors for its pulsed field ablation (PFA) system with a $35 million ...

"Supported by MAARS, clinicians can deliver personalized care to their patients and protect them appropriately from SCDA ...

Stereotaxis (NYSE:STXS) announced the publication of initial clinical results using its MAGiC robotic magnetic navigation ...

The funding will support the launch of the VERITAS trial while strengthening the company's clinical and regulatory ...

Field Medical has generated another $35 million in venture capital funding for its cardiac pulsed field ablation system to support the launch of a pivotal trial. | The series B financing comes quickly ...

Field Medical announced today that it has closed a Series B funding round worth proceeds totaling $35 million.

For ventricular tachycardia (VT), catheter ablation is often seen as an option of last resort, however, some are questioning whether there has been too much emphasis on antiarrhythmic medication.

Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.

BioStar Capital and Cue Growth co-lead financing to accelerate pivotal trial readiness and expand the ventricular tachycardia ...

In early June, a paper from researchers from the Biomedical Research Centre (BMC) of the Slovak Academy of Sciences led by ...